RXWell to Decrease Post-Operative Opioid Use in Total Knee or Hip Arthroplasty
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-100
SponsorUniversity of Pittsburgh
About this trial
It is envisioned that multipronged benefits from this pilot work for the UPMC ISD and its members. It is expected the RxWell platform to provide the following benefits: expansion of the use of RxWell to all UPMC ISD members providing peri-operative mood management with advantage of improved peri-operative outcomes, improving saving for the UPMC ISD by hastening the recovery and decreased resource utilization, and addition to the high-value care of UPMC with this holistic approach to patient perioperative care
Eligibility criteria
Qualifiers
Adults >18 years
Scheduled for elective primary total knee arthroplasty (TKA) or hip replacement (THA) at the approved UPMC hospitals
Moderately high levels of mood disorder symptoms on validated PROMIS measures, defined as a T-score > or = to 60 on PROMIS Anxiety 4a short form and/or PROMIS Depression4a short form
Disqualifiers
Patients undergoing non-elective surgery or secondary arthroplasty
Active delirium, neurocognitive impairment, or severe intellectual disability
No access to a smart device (phone or tablet)
Active alcoholism (defined as daily use of more than 1 liter of wine and /or 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)
Trial design
Treatments tested in this trial
- +RxWell
- -RxWell
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
University of Pittsburgh
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov